Medtronic PLC $MDT Shares Sold by Blue Trust Inc.

Blue Trust Inc. trimmed its position in shares of Medtronic PLC (NYSE:MDT) by 5.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,090 shares of the medical technology company’s stock after selling 559 shares during the period. Blue Trust Inc.’s holdings in Medtronic were worth $792,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MDT. Brighton Jones LLC boosted its stake in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the period. GAMMA Investing LLC lifted its stake in shares of Medtronic by 41.1% in the 1st quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company’s stock worth $1,427,000 after acquiring an additional 4,626 shares during the period. Relyea Zuckerberg Hanson LLC lifted its stake in shares of Medtronic by 28.5% in the 1st quarter. Relyea Zuckerberg Hanson LLC now owns 4,014 shares of the medical technology company’s stock worth $361,000 after acquiring an additional 890 shares during the period. Everhart Financial Group Inc. acquired a new stake in shares of Medtronic in the 1st quarter worth approximately $267,000. Finally, Stanley Laman Group Ltd. lifted its stake in shares of Medtronic by 11.4% in the 1st quarter. Stanley Laman Group Ltd. now owns 3,137 shares of the medical technology company’s stock worth $282,000 after acquiring an additional 321 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William R. Jellison acquired 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was purchased at an average cost of $92.37 per share, with a total value of $230,925.00. Following the purchase, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.26% of the company’s stock.

Medtronic Stock Down 1.0%

MDT stock opened at $95.52 on Friday. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $99.37. The firm has a market cap of $122.52 billion, a PE ratio of 26.31, a P/E/G ratio of 2.51 and a beta of 0.78. The firm has a 50 day simple moving average of $93.56 and a 200 day simple moving average of $88.74. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. During the same period in the prior year, the business earned $1.23 earnings per share. The business’s quarterly revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Investors of record on Friday, September 26th will be paid a $0.71 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is currently 78.24%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on MDT shares. The Goldman Sachs Group reduced their price target on shares of Medtronic from $82.00 to $81.00 and set a “sell” rating for the company in a research note on Wednesday, October 1st. Argus upped their price target on shares of Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, August 26th. Sanford C. Bernstein upped their price target on shares of Medtronic from $97.00 to $98.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 20th. Leerink Partners started coverage on shares of Medtronic in a research note on Monday, June 16th. They issued an “outperform” rating and a $110.00 price target for the company. Finally, UBS Group upped their price target on shares of Medtronic from $94.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 20th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and an average target price of $102.41.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.